MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1016/j.ocarto.2025.100737

Медицинская библиотека · Osteoarthritis and cartilage open · 2025

A randomized, double-blind, placebo-controlled and dose-ranging study to evaluate the safety and efficacy of XG005 in subjects with painful osteoarthritis of the knee.

Ren Limin, Zheng Wenjie, Guan Zhenpeng, Zhang Yang, Huang Zeyu, Li Tong, Peng Yuwei, Wu Qiuli, Gou Wei, Zhao Wei, Qiao Pengyan, Pan Xiaoli, Jiang Guang-Liang

СтатьяПеревод в очереди

Аннотация

OBJECTIVE

Symptomatic treatment for osteoarthritis (OA) remains a major unmet need. This trial evaluated XG005, a novel, non-opioid, dual-mechanism agent targeting both inflammatory and neuropathic pathways in patients with knee OA.

DESIGN

This randomized, double-blind, placebo-controlled study enrolled 318 patients with moderate-to-severe knee OA pain to receive XG005 750 mg, 500 mg, or placebo twice daily for 4 weeks. Efficacy measures included weekly average of daily walking pain (WADWP), Western Ontario and McMasters Universities Osteoarthritis Index (WOMAC), Knee Injury and Osteoarthritis Outcome Score (KOOS), Patient Global Impression of Change (PGIC), Sleep Interference Score (SIS), and Short-Form-12 Health Survey (SF-12).

RESULTS

The primary efficacy endpoint of improvement from baseline in WADWP at week 4 was statistically greater for the 750 mg group than placebo with least squares mean difference (LSMD) (95 % CI) of -0.55 (-0.94, -0.16). Key secondary endpoints were significantly improved for high- and low-dose XG005 compared to placebo at week 4, with LSMD (95 % CI) of -0.43 (-0.74, -0.13) and -0.4 (-0.78, -0.02) in WOMAC pain, and 5.56 (2.69, 8.42) and 3.74 (0.17, 7.31) in KOOS pain. WOMAC and KOOS stiffness and function, PGIC, SIS and SF-12 mental and general health showed statistically significant improvements over placebo. Patients with neuropathic pain had approximately 2-3-fold greater symptom improvements than patients with nociceptive pain. Mild dizziness and somnolence were most seen in XG005 groups.

CONCLUSION

XG005 demonstrated consistent efficacy in improving OA symptoms with acceptable tolerability. Additional studies in OA patients with neuropathic pain are needed to confirm its dual mechanism advantages.

CLINICAL TRIAL REGISTRATION: CTR20222406.

Для цитирования: Ren Limin, Zheng Wenjie, Guan Zhenpeng, Zhang Yang, Huang Zeyu, Li Tong, Peng Yuwei, Wu Qiuli, Gou Wei, Zhao Wei, Qiao Pengyan, Pan Xiaoli, Jiang Guang-Liang. A randomized, double-blind, placebo-controlled and dose-ranging study to evaluate the safety and efficacy of XG005 in subjects with painful osteoarthritis of the knee.. Osteoarthritis and cartilage open. 2025. DOI: 10.1016/j.ocarto.2025.100737.
Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.